NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience
BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflam...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A219-A219 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A219 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A219 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 27 |
| creator | Martín-Gutiérrez, N Sánchez-Hernández, J G Rebollo-Díaz, N Fernández-Pordomingo, A Muñoz-Núñez, J F Recarey-Gerpe, V Otero-López, MJ |
| description | BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflammatory bowel disease (IBD) over 2 years.Materials and methodsProspective, longitudinal study (April 2017–March 2019). Patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with originator infliximab (Remicade) and changed to biosimilar (CT-P13) were included.The following outcome variables were defined: Clinical Remission (CR)= Harvey Bradshaw index |
| doi_str_mv | 10.1136/ejhpharm-2020-eahpconf.468 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2552758570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552758570</sourcerecordid><originalsourceid>FETCH-LOGICAL-p808-e6ac5fe12506ff896eacf94f8e1fd7558c54ce7e02f4cd00706296a2fe60b50f3</originalsourceid><addsrcrecordid>eNo9jU1OwzAUhC0EElXpHSxYpzhO7DjsUMWfVAGL7qsX91lxceJgu2q7Y8MVOCAnoSqI1Yzmk74h5DJn0zwv5DWu26GF0GWccZYhtIP2vZmWUp2QEWdlldW1LE__u5DnZBKjbZgoClWXRT0iX8-vGcvZ98fnzNneanAU-hU9ekH7N9tjspoGjBuXIgWTMNDUIo1bm3RLk6e2N87ubAcNbayPtrMOwmE9Aug6SD7saeO36OjKRoSIN5TTPUKI1JuDG1zmrEGKuwGDxV7jBTkz4CJO_nJMFvd3i9ljNn95eJrdzrNBMZWhBC0M5lwwaYyqJYI2dWkU5mZVCaG0KDVWyLgp9YqxikleS-AGJWsEM8WYXP1qh-DfNxjTcu03oT88LrkQvBJKVKz4AchbceI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552758570</pqid></control><display><type>article</type><title>NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Martín-Gutiérrez, N ; Sánchez-Hernández, J G ; Rebollo-Díaz, N ; Fernández-Pordomingo, A ; Muñoz-Núñez, J F ; Recarey-Gerpe, V ; Otero-López, MJ</creator><creatorcontrib>Martín-Gutiérrez, N ; Sánchez-Hernández, J G ; Rebollo-Díaz, N ; Fernández-Pordomingo, A ; Muñoz-Núñez, J F ; Recarey-Gerpe, V ; Otero-López, MJ</creatorcontrib><description>BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflammatory bowel disease (IBD) over 2 years.Materials and methodsProspective, longitudinal study (April 2017–March 2019). Patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with originator infliximab (Remicade) and changed to biosimilar (CT-P13) were included.The following outcome variables were defined: Clinical Remission (CR)= Harvey Bradshaw index <5 in CD or partial Mayo index <3 in CU; Endoscopic Remission (ER)= mucosa healing with absence of ultrasound activity; Biochemical Remission (BR)= fecal calprotectin <100 mg/Kg.Infliximab serum concentrations were determined by ELISA and pharmacokinetic parameters (volume of distribution (Vd) and clearance (CL)) were estimated by Bayesian population pharmacokinetics analysis.Evaluation of variables was performed in four temporal sections: prior to the switch, immediately after, and again 8 months and 2 years after.ANOVA test was used to compare pharmacokinetic parameters means and the percentage of patients who reached the outcome variables in the different temporal sections was calculated.Results42 patients (55% women) were included, with a median [range] age of 42 [18-70] years, 10 diagnosed of UC and 32 of CD.Prior to the switch, 93% of the patients presented CR and ER, and 95% BR. These results were identical immediately after switching. Eight months after the switch, 93% of the patients presented CR and 88% ER and BR. At the end of the two years’ follow-up, 97% presented CR and 92% ER and BR.Regarding pharmacokinetic behaviour, there were no significant differences between the average values of CL estimated in the different sections, which were: 0.393 L/d; 0.392 L/d; 0,395 L/d and 0,390 L/d (p=0.91), nor among the Vd, whose results were: 5.25 L; 5.25 L; 5.24 L and 5.28 L (p=0.93), respectively.ConclusionAfter switching from infliximab originator to biosimilar in a real cohort of IBD patients, no changes in clinical outcomes or pharmacokinetic behaviour were observed over 2 years, which supports the switch in clinical practice.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-eahpconf.468</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Biological products ; Inflammatory bowel disease ; Monoclonal antibodies ; Pharmacokinetics ; Remission (Medicine) ; TNF inhibitors</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A219-A219</ispartof><rights>2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Martín-Gutiérrez, N</creatorcontrib><creatorcontrib>Sánchez-Hernández, J G</creatorcontrib><creatorcontrib>Rebollo-Díaz, N</creatorcontrib><creatorcontrib>Fernández-Pordomingo, A</creatorcontrib><creatorcontrib>Muñoz-Núñez, J F</creatorcontrib><creatorcontrib>Recarey-Gerpe, V</creatorcontrib><creatorcontrib>Otero-López, MJ</creatorcontrib><title>NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflammatory bowel disease (IBD) over 2 years.Materials and methodsProspective, longitudinal study (April 2017–March 2019). Patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with originator infliximab (Remicade) and changed to biosimilar (CT-P13) were included.The following outcome variables were defined: Clinical Remission (CR)= Harvey Bradshaw index <5 in CD or partial Mayo index <3 in CU; Endoscopic Remission (ER)= mucosa healing with absence of ultrasound activity; Biochemical Remission (BR)= fecal calprotectin <100 mg/Kg.Infliximab serum concentrations were determined by ELISA and pharmacokinetic parameters (volume of distribution (Vd) and clearance (CL)) were estimated by Bayesian population pharmacokinetics analysis.Evaluation of variables was performed in four temporal sections: prior to the switch, immediately after, and again 8 months and 2 years after.ANOVA test was used to compare pharmacokinetic parameters means and the percentage of patients who reached the outcome variables in the different temporal sections was calculated.Results42 patients (55% women) were included, with a median [range] age of 42 [18-70] years, 10 diagnosed of UC and 32 of CD.Prior to the switch, 93% of the patients presented CR and ER, and 95% BR. These results were identical immediately after switching. Eight months after the switch, 93% of the patients presented CR and 88% ER and BR. At the end of the two years’ follow-up, 97% presented CR and 92% ER and BR.Regarding pharmacokinetic behaviour, there were no significant differences between the average values of CL estimated in the different sections, which were: 0.393 L/d; 0.392 L/d; 0,395 L/d and 0,390 L/d (p=0.91), nor among the Vd, whose results were: 5.25 L; 5.25 L; 5.24 L and 5.28 L (p=0.93), respectively.ConclusionAfter switching from infliximab originator to biosimilar in a real cohort of IBD patients, no changes in clinical outcomes or pharmacokinetic behaviour were observed over 2 years, which supports the switch in clinical practice.</description><subject>Biological products</subject><subject>Inflammatory bowel disease</subject><subject>Monoclonal antibodies</subject><subject>Pharmacokinetics</subject><subject>Remission (Medicine)</subject><subject>TNF inhibitors</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo9jU1OwzAUhC0EElXpHSxYpzhO7DjsUMWfVAGL7qsX91lxceJgu2q7Y8MVOCAnoSqI1Yzmk74h5DJn0zwv5DWu26GF0GWccZYhtIP2vZmWUp2QEWdlldW1LE__u5DnZBKjbZgoClWXRT0iX8-vGcvZ98fnzNneanAU-hU9ekH7N9tjspoGjBuXIgWTMNDUIo1bm3RLk6e2N87ubAcNbayPtrMOwmE9Aug6SD7saeO36OjKRoSIN5TTPUKI1JuDG1zmrEGKuwGDxV7jBTkz4CJO_nJMFvd3i9ljNn95eJrdzrNBMZWhBC0M5lwwaYyqJYI2dWkU5mZVCaG0KDVWyLgp9YqxikleS-AGJWsEM8WYXP1qh-DfNxjTcu03oT88LrkQvBJKVKz4AchbceI</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Martín-Gutiérrez, N</creator><creator>Sánchez-Hernández, J G</creator><creator>Rebollo-Díaz, N</creator><creator>Fernández-Pordomingo, A</creator><creator>Muñoz-Núñez, J F</creator><creator>Recarey-Gerpe, V</creator><creator>Otero-López, MJ</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200301</creationdate><title>NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience</title><author>Martín-Gutiérrez, N ; Sánchez-Hernández, J G ; Rebollo-Díaz, N ; Fernández-Pordomingo, A ; Muñoz-Núñez, J F ; Recarey-Gerpe, V ; Otero-López, MJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p808-e6ac5fe12506ff896eacf94f8e1fd7558c54ce7e02f4cd00706296a2fe60b50f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biological products</topic><topic>Inflammatory bowel disease</topic><topic>Monoclonal antibodies</topic><topic>Pharmacokinetics</topic><topic>Remission (Medicine)</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martín-Gutiérrez, N</creatorcontrib><creatorcontrib>Sánchez-Hernández, J G</creatorcontrib><creatorcontrib>Rebollo-Díaz, N</creatorcontrib><creatorcontrib>Fernández-Pordomingo, A</creatorcontrib><creatorcontrib>Muñoz-Núñez, J F</creatorcontrib><creatorcontrib>Recarey-Gerpe, V</creatorcontrib><creatorcontrib>Otero-López, MJ</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martín-Gutiérrez, N</au><au>Sánchez-Hernández, J G</au><au>Rebollo-Díaz, N</au><au>Fernández-Pordomingo, A</au><au>Muñoz-Núñez, J F</au><au>Recarey-Gerpe, V</au><au>Otero-López, MJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2020-03-01</date><risdate>2020</risdate><volume>27</volume><issue>Suppl 1</issue><spage>A219</spage><epage>A219</epage><pages>A219-A219</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflammatory bowel disease (IBD) over 2 years.Materials and methodsProspective, longitudinal study (April 2017–March 2019). Patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with originator infliximab (Remicade) and changed to biosimilar (CT-P13) were included.The following outcome variables were defined: Clinical Remission (CR)= Harvey Bradshaw index <5 in CD or partial Mayo index <3 in CU; Endoscopic Remission (ER)= mucosa healing with absence of ultrasound activity; Biochemical Remission (BR)= fecal calprotectin <100 mg/Kg.Infliximab serum concentrations were determined by ELISA and pharmacokinetic parameters (volume of distribution (Vd) and clearance (CL)) were estimated by Bayesian population pharmacokinetics analysis.Evaluation of variables was performed in four temporal sections: prior to the switch, immediately after, and again 8 months and 2 years after.ANOVA test was used to compare pharmacokinetic parameters means and the percentage of patients who reached the outcome variables in the different temporal sections was calculated.Results42 patients (55% women) were included, with a median [range] age of 42 [18-70] years, 10 diagnosed of UC and 32 of CD.Prior to the switch, 93% of the patients presented CR and ER, and 95% BR. These results were identical immediately after switching. Eight months after the switch, 93% of the patients presented CR and 88% ER and BR. At the end of the two years’ follow-up, 97% presented CR and 92% ER and BR.Regarding pharmacokinetic behaviour, there were no significant differences between the average values of CL estimated in the different sections, which were: 0.393 L/d; 0.392 L/d; 0,395 L/d and 0,390 L/d (p=0.91), nor among the Vd, whose results were: 5.25 L; 5.25 L; 5.24 L and 5.28 L (p=0.93), respectively.ConclusionAfter switching from infliximab originator to biosimilar in a real cohort of IBD patients, no changes in clinical outcomes or pharmacokinetic behaviour were observed over 2 years, which supports the switch in clinical practice.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2020-eahpconf.468</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A219-A219 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_proquest_journals_2552758570 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biological products Inflammatory bowel disease Monoclonal antibodies Pharmacokinetics Remission (Medicine) TNF inhibitors |
| title | NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A59%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NP-010%E2%80%85Clinical%20and%20pharmacokinetic%20results%20after%20the%20switch%20to%20infliximab%20biosimilar%20in%20inflammatory%20bowel%20disease:%202%20years%20of%20real-life%20experience&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Mart%C3%ADn-Guti%C3%A9rrez,%20N&rft.date=2020-03-01&rft.volume=27&rft.issue=Suppl%201&rft.spage=A219&rft.epage=A219&rft.pages=A219-A219&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-eahpconf.468&rft_dat=%3Cproquest%3E2552758570%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552758570&rft_id=info:pmid/&rfr_iscdi=true |